Severe COVID-19 Clinical Trial
Official title:
Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomised, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting.
Multinational, multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase III trial. It will enrol 526 male and female patients >18 years, hospitalised for CAP (including COVID-19), assigned (1:1) to receive either oral reparixin (treatment group) or matched placebo (control group) three times a day (TID) for up to 21 days. Randomisation will be stratified according to disease severity and site. All the patients will receive the standard of care based on their clinical need, including COVID-19 and CAP medications, as per local standard therapy at the trial site and in line with international guidelines. The primary outcome will be evaluated at day 28, secondary will be evaluated from day 3 to day 180. An independent external data monitoring committee (DMC) will oversee the study and evaluate unblinded interim data for efficacy, futility, and safety. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05175833 -
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
|
Phase 2 | |
| Recruiting |
NCT05256511 -
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
|
||
| Completed |
NCT04866082 -
Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
|
||
| Active, not recruiting |
NCT04918901 -
Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
|
||
| Recruiting |
NCT05233605 -
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
|
||
| Not yet recruiting |
NCT04613986 -
Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
|
N/A | |
| Recruiting |
NCT05447013 -
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04733833 -
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
|
Phase 2 | |
| Recruiting |
NCT04712344 -
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)
|
Phase 2 | |
| Terminated |
NCT04713176 -
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
|
Phase 3 | |
| Recruiting |
NCT04648410 -
Corticosteroids in Severe COVID-19(ASAP-C Study)
|
||
| Enrolling by invitation |
NCT06235866 -
Risk Identification of Long-term Complications
|
||
| Completed |
NCT05596617 -
Safety and Efficacy of Medications COVID-19
|
N/A |